Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SN6V
|
|||
| Former ID |
DNC008221
|
|||
| Drug Name |
T-BuAc-RYYRIK-NH2
|
|||
| Synonyms |
CHEMBL270216
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C48H78N14O8
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCCN=C(N)N)NC(=O)CC(C)(C)C
|
|||
| InChI |
1S/C48H78N14O8/c1-6-29(2)39(45(70)58-33(40(50)65)16-10-11-23-49)62-42(67)35(18-13-25-56-47(53)54)59-43(68)37(27-31-19-21-32(63)22-20-31)61-44(69)36(26-30-14-8-7-9-15-30)60-41(66)34(17-12-24-55-46(51)52)57-38(64)28-48(3,4)5/h7-9,14-15,19-22,29,33-37,39,63H,6,10-13,16-18,23-28,49H2,1-5H3,(H2,50,65)(H,57,64)(H,58,70)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
|
|||
| InChIKey |
MBLODLLZWHUJED-INYUMPDKSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.